DBL Cisplatin Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Cisplatin

Indications/Uses

Palliative treatment of metastatic non-seminomatous germ cell carcinoma, advanced-stage refractory ovarian & bladder carcinoma, & refractory squamous cell carcinoma of the head & neck, as monotherapy or in combination w/ other chemotherapeutic agents. May be employed in addition to other modalities (eg, radiotherapy or surgery).

Dosage/Direction for Use

IV Adult & childn Monotherapy: 50-100 mg/m² as single infusion every 3-4 wk or 15-20 mg/m² daily infusion for 5 days every 3-4 wk. Administer infusion over 1-2 hr, longer infusion time of 6-8 hr may decrease GI & renal toxicities.

Contraindications

History of hypersensitivity to cisplatin or other platinum-containing compd. Hearing disorders. Bone marrow depression. Generalised infections. Renal impairment. Pregnancy & lactation.

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01XA01 - cisplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

DBL Cisplatin inj 1 mg/mL

Packing/Price

1's

DBL Cisplatin

cisplatin

Manufacturer:

Hospira Australia